There are 105 resources available
Q&A and live discussion
Presenter: Andres Cervantes
Session: Presidential Symposium III
Resources:
Webcast
LBA6_PR - Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study
Presenter: Markus Moehler
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA8_PR - Pembrolizumab plus chemotherapy versus chemotherapy as first-line therapy in patients with advanced esophageal cancer: The phase 3 KEYNOTE-590 study
Presenter: Ken Kato
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA9_PR - Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiation therapy (CRT): First results of the CheckMate 577 study
Presenter: Ronan Kelly
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
LBA7_PR - Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
Presenter: Narikazu Boku
Session: Presidential Symposium III
Resources:
Abstract
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.